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 INTRODUCTION
Acute kidney injury (AKI) is common and the abso-
lute incidence of AKI has increased over the last dec-
ade1. Almost 10% of hospitalized patients can develop 
AKI; incidence is even greater in the intensive care 
unit (ICU) and emergency department (ED) settings, 
respectively attaining 30% and 20% in Portugal2,3. AKI 
is a complex syndrome that occurs in many different 
settings, resulting from different insults, with a wide 
variety of subtypes and with diverse aetiologies. AKI 
can manifest from small increases in serum creatinine 
(SCr) to the urgent need for renal replacement therapy 
(RRT). AKI has a well-documented negative impact on 
kidney and patient survival in the short- and long-
term1. Serum creatinine is an imprecise and delayed 
marker of AKI. Extensive pre-clinical and clinical 
research on AKI biomarkers has opened up a new era 
in this field. It has been asserted that more timely 
diagnosis using novel AKI biomarkers would allow 
earlier intervention and could improve patient out-
comes. Herein we aim to summarize the major studies 
that have characterized the diagnostic and prognostic 
predictive power of novel AKI biomarkers, together 
with our experience.
 AKI BIOMARKERS: WHERE WE ARE
A biomarker is a measurable indicator of normal 
biological or pathological processes and/or the 
expression of response to some intervention. Novel 
AKI biomarkers have undoubtedly attained an impor-
tant role in diagnosis, prognosis and even prediction, 
not just for AKI but also for associated outcomes, but 
only in specific research fields. The question of how 
to optimally use them at the bedside is still unre-
solved. Despite the large number and extent of bio-
markers proposed over the last decade, our high 
expectations have not been followed by a reliable 
change in our clinical practice. Apparently, we have 
not found sufficient reasons to abandon SCr, despite 
its limitations.
We could benefit from early AKI diagnosis if we had 
a kidney-specific biomarker to avoid iatrogenic inter-
ventions, attenuate damage and enhance recovery. 
Earlier AKI diagnosis may identify patients with mild 
AKI that may not be recognized by clinicians. Given the 
current lack of effective pharmacologic interventions 
for AKI, early recognition should mainly address reduc-
ing the risk of injury progression. This risk assessment 
for AKI has been recommended by clinical practice 
guidelines4.
The performance of AKI biomarkers is influenced by 
many factors: settings, population studied, time of 
measurement after insult, threshold diagnosis of AKI 
and study design, among others. All are closely related 
to the complexity of the pathogenesis and pathobiology 
of the AKI syndrome. This has been demonstrated by 
the lower test performance of six biomarkers in AKI 
patients with pre-existing CKD5.
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  RELEVANT BIOMARKERS CURRENTLY 
USED IN RESEARCH
The biomarkers deemed most relevant in research in 
the last decade include functional biomarkers (SCr, and 
serum cystatin C (CysC)); markers of tubular damage such 
as tubular enzymes (γ-glutamyl transpeptidase (GGT), 
N-acetyl-β- glucosaminidase, α-glutathione-S trans-
ferase); non-absorbed tubular proteins (urinary CysC, 
albuminuria, β2-microglobulin and α1-microglobulin); or 
upregulated proteins induced by tubular injury (kidney 
injury molecule 1 (KIM-1), neutrophil gelatinase–associ-
ated lipocalin (NGAL), interleukin-18 (IL-18), liver-type 
fatty acid-binding protein (L-FABP) and recently, cell cycle 
arrest proteins such as tissue inhibitor of metalloprotein-
ase-2 (TIMP-2) and IGF-binding protein 7 (IGFBP7)).
Several previous studies were limited by reliance on 
a single measurement of biomarkers. Recent studies 
have revealed a distinct temporal profile for AKI bio-
markers6. In the Emergency Department (ED) setting, 
the temporal profile of plasma NGAL (pNGAL) and 
serum CysC (SCysC) for AKI diagnosis showed peaks at 
12h from admission and performance at that time was 
the best2,3.
Owing to the broad range of published results and 
several in-depth reviews, we would conclude that the 
most relevant biomarkers with potential for use in clini-
cal practice are those able to detect structural kidney 
damage, such as pNGAL and urinary NGAL (uNGAL), 
KIM-1, IL-18, L-FABP, and TIMP-2, and IGFBP7. Despite 
more than a decade of intensive research efforts, the 
role of those markers at the bedside for decision mak-
ing remains unclear. However, SCysC performed better 
than SCr as a filtration marker and for risk stratification; 
IL-18 and uNGAL preceded SCr and were associated to 
AKI risk and adverse outcomes such as RRT and death, 
both improving the clinical prediction model7,8. The 
current status of the most promising AKI biomarkers 
is shown in Table 1.
The NGAL gene is primarily induced in the distal 
nephron; NGAL protein can be found in both the distal 
and the proximal nephron., NGAL protein found in the 
proximal nephron reflects megalin-dependent avid 
reabsorption of filtered NGAL by the proximal tubule. 
Therefore NGAL possesses many characteristics of a 
good AKI biomarker. It is rapidly induced and released 
from the injured distal nephron; pNGAl and uNGAL 
concentrations increase proportionally in line with the 
severity and duration of injury; and it rapidly decreases 
with attenuation of AKI9. pNGAL can detect patients 
with probable subclinical AKI who are at increased risk 
of adverse outcomes, in the absence of SCr changes3,9. 
Despite all these positive characteristics, both uNGAL 
and pNGAL have shown mixed results in a number of 
studies. Standardized clinical platforms for the routine 
clinical measurement of NGAL are now widely available. 
In a recent decision analysis model, the use of uNGAL 
was shown to represent an economically advantageous 
strategy for the early diagnosis of AKI in patients under-
going cardiac surgery10.
In the ED setting, among 5 urinary biomarkers (NGAL, 
KIM-1, LFABP, IL-18 and CysC), uNGAL enables prospec-
tive diagnostic and prognostic stratification of AKI, as 
it is able to distinguish between preAKI, stable CKD and 
normal function11. We also have shown this discrimina-
tive ability of SCysC and pNGAL2,3. As markers of poor 
outcomes (RRT, CKD, and death), uNGAL and KIM-1 
were the most accurate predictors.
TIMP-2 and IGFBP7 are cell-cycle arrest proteins 
expressed in kidney tubular cells during cellular stress 
or injury. By detecting both proteins in the urine, we 
detect cell stress at the earliest point. However, this stress 
may or may not lead to damage and dysfunction13. Both 
Table 1
Main abilities of AKI biomarkers according to reviewed literature
Biomarker
Kidney 
specificity
Improving Diagnosis Improving Prognosis
early discriminative
grading 
severity
recovery etiology
AKI  
progression
RRT CKD mortality
Serum Cystatin C √ √ √ √ √
uNGAL/pNGAL √ √ √ √ √ √ √ √
KIM-1 √ √ √ √ √ √ √ √
L-FABP √ √ √ √ √
[TIMP-2]-[IGFBP7] √ √ √ √ √ √ √
AKI, acute kidney injury; RRT. Renal replacement therapy; CKD, chronic kidney disease; NGAL, neutrophil gelatinase–associated lipocalin (uNGAL, urinary; pNGAL, plasma); KIM-1, 
kidney injury molecule 1; L-FABP, liver-type fatty acid-binding protein; TIMP-2, tissue inhibitor of metalloproteinase-2; and IGFBP7, IGF-binding protein 7.
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proteins are capable of inducing a wide variety of cellular 
response, whereby their presumed role as inducers of 
G1 cell cycle arrest remains speculative14. In discovery 
phase, 340 different proteins were examined; urinary 
IGFBP7 and TIMP-2 were the best-performing markers15. 
In a second multicentre study, SAPPHIRE, both markers 
were validated as being able to predict the onset of 
severe AKI (KDIGO stage 2 or 3) more accurately than 
uNGAL, KIM-1, IL-18, L-FABP or urinary cystatin C. [TIMP-
2]-[IGFBP7] showed improved performance for risk 
stratification, risk of adverse events such as RRT, persis-
tent kidney dysfunction and death. The multicentre 
TOPAZ study validated the high-sensitivity cutoff value 
of [TIMP-2]-[IGFBP7] for risk assessment of AKI, diag-
nosed by clinical adjudication in critically ill patients16. 
But high sensitivity (92%) was associated to low specific-
ity (46%). Hence, false-positive results may be common 
and magnified if the test is used in low-risk patients.
A bedside device test was developed for simultane-
ous measurement of [TIMP-2]-[IGFBP7]: the NEPHRO-
CHECK Test (ASTUTE140 Meter), which takes 20 min-
utes, performing only one test at a time. The Food and 
Drug Administration has approved it for AKI risk detec-
tion but its cost benefit is still unknown. More recently, 
several studies have shown the improved performance 
of this test in assessing the risk for AKI and predicting 
outcomes17. Nevertheless, the optimal role of this bio-
marker in different clinical settings requires further 
clarification. The ASN advisory group emphasizes that 
this test should only be used in ICU patients >21 years 
of age with cardiovascular and/or respiratory compro-
mise within the previous 24h. It should therefore not 
be used for point-of-care testing.
  MOVING FORWARD CLINICAL 
APPLICATIONS OF BIOMARKERS
For a biomarker to be transferred to our daily clinical 
practice, it is essential to consider the clinical setting, 
and also to plan which clinical intervention or care we 
must implement in response to a biomarker increase. 
We propose a stratification of the risk of AKI depending 
on pNGAL levels, identifying a high-risk zone encom-
passing patients who are likely to benefit from intensive 
monitoring and treatment; a moderate-risk or grey 
zone, for those who require re-evaluation or the addi-
tion of a different associated biomarker; and a low-risk 
zone, for those patients in whom surveillance can be 
safely reduced. We have shown that both SCysC and 
pNGAL rise before SCr, at 12h from study admission, 
and, therefore, these markers are able to predict the 
development of AKI and allow the institution of early 
goal-directed therapy (change doses of medication and 
increase haemodinamic support to improve haemody-
namic status) aiming at AKI risk reduction. Moreover, 
these patients should be closely followed after dis-
charge because they frequently develop CKD and End 
Stage Renal Disease8. In cases with increased SCr due 
to transient azotaemia, the absence of an increase in 
a structural AKI biomarker such as pNGAL would indi-
cate a functional volume-responsive AKI, with an 
improved prognosis. A suggested approach for the use 
of pNGAL in the clinical setting is shown in Table 2.
But above all, we must include the clinical context 
in biomarker performance. Patient-dependent variables 
such as demographic characteristics and comorbidities 
should be taken into account to evaluate the risk of 
AKI and associated outcomes, as we have shown that 
age, kidney susceptibility and cardiovascular disease 
are critical in ED for AKI development, as well as for 
adverse outcomes such as CKD and death8.
In recent years, electronic alert systems have been 
proposed for early detection of AKI using current defini-
tion criteria, with the goal of warning clinicians early 
and optimizing intervention. The Acute Dialysis Quality 
Initiative (ADQI) workgroup has encouraged develop-
ment of this tool for early AKI detection18.
AKI diagnosis based on SCr may represent a misdi-
agnosis more frequently than we have thought. We 
have shown that pNGAL can increase in the absence 
of a significant rise of SCr, and during the follow-up 
Table 2
Proposed use of pNGAL in the clinical setting
Measure pNGAL only if AKI is clinically suspected
 False positives may include urinary tract infections and sepsis without AKI
<50 ng/ml
Low risk of AKI, repeat measures only if clinically indicated
50-150 ng/ml
Grey zone, repeat measures
150-300 ng/ml
High risk for structural tubular injury, obtain daily pNGAL measurements, 
monitor ins and outs, monitor electrolytes and kidney function, avoid 
nephrotoxins, avoid hypotension, consider Nephrology consult
>300 ng/ml
High risk for severe structural tubular injury, obtain daily pNGAL measure-
ments, keep in ICU setting, closely monitor ins and outs, closely monitor 
electrolytes and kidney function, avoid nephrotoxins, avoid hypotension, 
obtain Nephrology consult, strongly consider early interventions 
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time it could be associated to CKD evolution8. So 
should the current AKI definition based on SCr be 
changed?
There is no sense in using a biomarker for AKI diag-
nosis when the diagnosis is clinically evident and bio-
chemically confirmed. In such cases, it is useful to utilize 
a biomarker to forecast or predict progression, RRT 
need or recovery.
Some studies have shown very impressive results 
and concur with the concept that AKI biomarkers have 
the potential to transform current AKI diagnosis criteria. 
Conversely, we still confront significant unresolved con-
cerns that currently hamper efforts to bring biomarkers 
from the bench to the bedside.
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